Arch Biopartners wins central IRB approval for Phase II LSALT peptide CS-AKI trial in US

PUBT · 2d ago
Arch Biopartners wins central IRB approval for Phase II LSALT peptide CS-AKI trial in US
  • Arch Biopartners received central IRB clearance for its Phase II LSALT peptide trial in cardiac surgery-associated acute kidney injury.
  • Decision supports activation of planned U.S. sites, expanding recruitment beyond Canada and prior sites in Turkey.
  • Initial U.S. patient dosing expected in 4-6 months, subject to site start-up and remaining institutional approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310820PRIMZONEFULLFEED9818319) on August 31, 2026, and is solely responsible for the information contained therein.